GC Corp., the holding company for GC Group in South Korea with operating companies across healthcare sectors, has signed a definitive agreement to acquire 100% of the shares of BioCentriq, a U.S.-based contract development and manufacturing organization (CDMO) that designs and develops scalable cell and gene technologies. This cross-border acquisition broadens GC companies’ capabilities in scaling CDMO platforms. Founded in 2019 as a New Jersey Innovation Institute company, BioCentriq is well...